Mooy J, van Baak M, Böhm R, Does R, Petri H, van Kemenade J, Rahn K H
Clin Pharmacol Ther. 1987 May;41(5):490-5. doi: 10.1038/clpt.1987.63.
In a single-blind, placebo-controlled crossover study the effects of verapamil (450 +/- 30 mg/day) and propranolol (160 +/- 20 mg/day) on endurance time during submaximal exercise were compared in eight patients with essential hypertension. The drugs were given in randomized order. Each active drug period was preceded by a placebo phase. Endurance tests were performed during both placebo periods and treatment with verapamil and propranolol by bicycle ergometry. Both drugs were equally effective in decreasing resting blood pressure. Verapamil and propranolol reduced exercise heart rate, the effect of propranolol being more pronounced. With placebo, endurance time during exercise was 57 +/- 11 minutes; with propranolol it was 32 +/- 7 minutes (P less than 0.05). Verapamil had no influence on endurance time. The study demonstrates that in contrast to propranolol, verapamil has no influence on exercise tolerance during submaximal work in patients with hypertension.
在一项单盲、安慰剂对照的交叉研究中，对8例原发性高血压患者比较了维拉帕米（450±30毫克/天）和普萘洛尔（160±20毫克/天）对次极量运动期间耐力时间的影响。药物按随机顺序给予。每个活性药物期之前均有一个安慰剂阶段。通过自行车测力计在安慰剂期以及维拉帕米和普萘洛尔治疗期间进行耐力测试。两种药物在降低静息血压方面同样有效。维拉帕米和普萘洛尔均降低运动心率，普萘洛尔的效果更明显。使用安慰剂时，运动期间的耐力时间为57±11分钟；使用普萘洛尔时为32±7分钟（P<0.05）。维拉帕米对耐力时间无影响。该研究表明，与普萘洛尔不同，维拉帕米对高血压患者次极量运动期间的运动耐力无影响。
